Chuhan Chung

2.7k total citations · 2 hit papers
19 papers, 814 citations indexed

About

Chuhan Chung is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Chuhan Chung has authored 19 papers receiving a total of 814 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Epidemiology, 13 papers in Hepatology and 7 papers in Surgery. Recurrent topics in Chuhan Chung's work include Liver Disease Diagnosis and Treatment (16 papers), Liver Diseases and Immunity (11 papers) and Pediatric Hepatobiliary Diseases and Treatments (5 papers). Chuhan Chung is often cited by papers focused on Liver Disease Diagnosis and Treatment (16 papers), Liver Diseases and Immunity (11 papers) and Pediatric Hepatobiliary Diseases and Treatments (5 papers). Chuhan Chung collaborates with scholars based in United States, Austria and Canada. Chuhan Chung's co-authors include Robert P. Myers, G. Mani Subramanian, Eric Lawitz, Rohit Loomba, Andrew J. Muir, Michael Trauner, Stephen A. Harrison, Peter Ruane, Eliza Harting and Christopher L. Bowlus and has published in prestigious journals such as Gastroenterology, Hepatology and Journal of Hepatology.

In The Last Decade

Chuhan Chung

19 papers receiving 800 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

2018 257 citations Rohit Loomba, Zeid Kayali et al. Gastroenterology profile →
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

2019 205 citations Michael Trauner, Aliya Gulamhusein et al. Hepatology profile →

Peers

Countries citing papers authored by Chuhan Chung

Since Specialization

Citations

This map shows the geographic impact of Chuhan Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chuhan Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chuhan Chung more than expected).

Fields of papers citing papers by Chuhan Chung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chuhan Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chuhan Chung. The network helps show where Chuhan Chung may publish in the future.

Co-authorship network of co-authors of Chuhan Chung

This figure shows the co-authorship network connecting the top 25 collaborators of Chuhan Chung. A scholar is included among the top collaborators of Chuhan Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chuhan Chung. Chuhan Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis 2023 ·BMC Gastroenterology ·Michael Trauner, Chuhan Chung, (unknown), Xiangyu Liu, Xiaomin Lu, Jun Xu, Clare M. Tempany, Zachary Goodman, Martti Färkkilâ, Atsushi Tanaka, Palak Trivedi, Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy, Robert P. Myers	14
2	Integration of deep learning-based histopathology and transcriptomics reveals key genes associated with fibrogenesis in patients with advanced NASH 2023 ·Cell Reports Medicine ·Jake R. Conway, (unknown), Yevgeniy Gindin, David Z. Pan, Oscar Carrasco‐Zevallos, (unknown), G. Mani Subramanian, Michael Montalto, Murray B. Resnick, Andrew H. Beck, Ryan S. Huss, Robert P. Myers, Amaro Taylor‐Weiner, Ilan Wapinski, Chuhan Chung	12
3	Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate 2023 ·Journal of Lipid Research ·(unknown), (unknown), Sabrina A Mann, (unknown), Kelvin W. Li, (unknown), Jen‐Chieh Chuang, Kaiyi Zhu, Andrew N. Billin, Ryan S. Huss, Chuhan Chung, Robert P. Myers, Marc K. Hellerstein	9
4	Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients 2022 ·Journal of Lipid Research ·Eric Lawitz, Kelvin W. Li, Edna Nyangau, Tyler Field, Jen‐Chieh Chuang, Andrew N. Billin, Lulu Wang, Ya Wang, Ryan S. Huss, Chuhan Chung, G. Mani Subramanian, Robert P. Myers, Marc K. Hellerstein	19
5	Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC 2022 ·Clinical Gastroenterology and Hepatology ·Michael Trauner, Christopher L. Bowlus, Aliya Gulamhusein, Bilal Hameed, Stephen H. Caldwell, Mitchell L. Shiffman, Charles Landis, Andrew J. Muir, Andrew N. Billin, Jun Xu, Xiangyu Liu, Xiaomin Lu, Chuhan Chung, Robert P. Myers, Kris V. Kowdley	28
6	Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat 2022 ·Clinical Gastroenterology and Hepatology ·Eric Lawitz, Bal Raj Bhandari, Peter Ruane, Anita Kohli, Eliza Harting, Dora Ding, Jen‐Chieh Chuang, Ryan S. Huss, Chuhan Chung, Robert P. Myers, Rohit Loomba	34
7	Hepatic Deletion of X-Box Binding Protein 1 in FXR Null Mice Leads to Enhanced Liver Injury 2022 ·Journal of Lipid Research ·Xiaoying Liu, (unknown), Chuhan Chung, Yevgeniy Gindin, Susan C. Hubchak, (unknown), (unknown), (unknown), Wei Qiu, Xianzhong Ding, Deyu Fang, Richard Green	6
8	Multi stain graph fusion for multimodal integration in pathology 2022 ·2022 IEEE/CVF Conference on Computer Vision and Pattern Recognition Workshops (CVPRW) ·(unknown), (unknown), (unknown), (unknown), (unknown), Chuhan Chung, Timothy R. Watkins, Andrew N. Billin, Robert P. Myers, John H. Abel, Ali Behrooz	14
9	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis 2021 ·Hepatology ·Arun J. Sanyal, Quentin M. Anstee, Michael Trauner, Eric Lawitz, Manal F. Abdelmalek, Dora Ding, Ling Han, Catherine Jia, Ryan S. Huss, Chuhan Chung, Vincent Wai‐Sun Wong, Takeshi Okanoue, Manuel Romero‐Gómez, Andrew J. Muir, Nezam H. Afdhal, Jaime Bosch, Zachary Goodman, Stephen A. Harrison, Zobair M. Younossi, Robert P. Myers	89
10	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis 2020 ·Clinical Gastroenterology and Hepatology ·Palak Trivedi, Andrew J. Muir, Cynthia Levy, Christopher L. Bowlus, Michael P. Manns, Xiaomin Lu, Gerald Crans, Chuhan Chung, G. Mani Subramanian, Robert P. Myers, Zachary Goodman, Naga Chalasani, John M. Vierling, Indra Neil Guha, Gideon M. Hirschfield	34
11	Machine learning models identify novel histologic features predictive of clinical disease progression in patients with advanced fibrosis due to non-alcoholic steatohepatitis 2020 ·Journal of Hepatology ·(unknown), (unknown), (unknown), Benjamin Glass, Hunter Elliott, Ling Han, Catherine Jia, Ryan S. Huss, Chuhan Chung, Mani Subramanian, Robert P. Myers, Stephen A. Harrison, Zachary Goodman, Murray B. Resnick, Aditya Khosla, Andrew H. Beck, Ilan Wapinski, Arun J. Sanyal, Zobair M. Younossi	1
12	A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis 2020 ·Hepatology ·Yevgeniy Gindin, Chuhan Chung, Zhaoshi Jiang, (unknown), Jun Xu, Andrew N. Billin, Robert P. Myers, Zachary Goodman, Abdolamir Landi, Michael Houghton, Richard M. Green, Cynthia Levy, Kris V. Kowdley, Christopher L. Bowlus, Andrew J. Muir, Michael Trauner	10
13	The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC. 2019 ·Hepatology ·Michael Trauner, Aliya Gulamhusein, Bilal Hameed, Stephen H. Caldwell, Mitchell L. Shiffman, Charles Landis, Bertus Eksteen, Kosh Agarwal, Andrew J. Muir, Simon Rushbrook, Xiaomin Lu, Jun Xu, Jen‐Chieh Chuang, Andrew N. Billin, Chuhan Chung, Georgia Li, G. Mani Subramanian, Robert P. Myers, Christopher L. Bowlus, Kris V. Kowdley	3
14	Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis 2019 ·JHEP Reports ·Michael Trauner, Yevgeniy Gindin, Zhaoshi Jiang, Chuhan Chung, G. Mani Subramanian, Robert P. Myers, Aliya Gulamhusein, Kris V. Kowdley, Cynthia Levy, Zachary Goodman, Michael P. Manns, Andrew J. Muir, Christopher L. Bowlus	14
15	SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis 2019 ·Journal of Hepatology ·Eric Lawitz, Edward Gane, Peter Ruane, Robert Herring, Ziad Younes, Paul Y. Kwo, Jie Zhang, Catherine Jia, (unknown), B. Mccolgan, Chuhan Chung, Mani Subramanian, Robert P. Myers, Michael S. Middleton, Kelvin W. Li, Marc K. Hellerstein, Mazen Noureddin, Stephen A. Harrison, Rohit Loomba	9
16	PS-012-Validation of histologic and non-invasive measures of fibrosis as surrogate end points of disease progression in patients with primary sclerosing cholangitis 2019 ·Journal of Hepatology ·Christopher L. Bowlus, Mitchell L. Shiffman, Harry L.A. Janssen, Aldo J. Montaño‐Loza, Stephen H. Caldwell, Velimir A. Luketic, Xiaomin Lu, Gerald Crans, Chuhan Chung, Mani Subramanian, Robert P. Myers, Michael P. Manns, Cynthia Levy, Michael Trauner, Zachary Goodman, Andrew J. Muir	1
17	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis breakdown → 2019 ·Hepatology ·Michael Trauner, Aliya Gulamhusein, Bilal Hameed, Stephen H. Caldwell, Mitchell L. Shiffman, Charles Landis, Bertus Eksteen, Kosh Agarwal, Andrew J. Muir, Simon Rushbrook, Xiaomin Lu, Jun Xu, Jen‐Chieh Chuang, Andrew N. Billin, Georgia Li, Chuhan Chung, G. Mani Subramanian, Robert P. Myers, Christopher L. Bowlus, Kris V. Kowdley	205
18	GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease breakdown → 2018 ·Gastroenterology ·Rohit Loomba, Zeid Kayali, Mazen Noureddin, Peter Ruane, Eric Lawitz, Michael Bennett, Lulu Wang, Eliza Harting, Jacqueline M. Tarrant, B. Mccolgan, Chuhan Chung, Adrian S. Ray, G. Mani Subramanian, Robert P. Myers, Michael S. Middleton, Michelle Lai, Michael Charlton, Stephen A. Harrison	257
19	DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis 2018 ·JCI Insight ·Rohit Loomba, Yevgeniy Gindin, Zhaoshi Jiang, Eric Lawitz, Stephen H. Caldwell, C. Stephen Djedjos, Ren Xu, Chuhan Chung, Robert P. Myers, G. Mani Subramanian, Zachary Goodman, Michael Charlton, Nezam H. Afdhal, Anna Mae Diehl	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact